retatrutide clinical trial results safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Investigating the “efficacy and safety

Wondering why semaglutide can make you tired

What Sets Retatrutide Apart

Experiencing vertigo or dizziness from GLP-1 Injections

This gentle daily supplement supports steady digestion, regularity, and microbiome health as your body adjusts to new eating patterns

Een nieuwe studie, die onlangs is gepubliceerd in JAMA Network Open, suggereert dat GLP-1 (glucagon-like peptide-1) receptoragonisten, die momenteel goedgekeurd zijn voor de behandeling van diabetes en obesitas, mogelijk een bijkomend voordeel hebben: ze kunnen het risico op bepaalde met obesitas geassocieerde kankers (obesity associated cancers, OACs) verminderen

Read first-hand success stories from our members about the positive changes members are experiencing with Levitys evidence-based weight loss programme.